Literature DB >> 91856

Pergolide and lisuride for Parkinson's disease.

A N Lieberman, M Leibowitz, A Neophytides, M Kupersmith, S Mehl, D Kleinberg, M Serby, M Goldstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 91856     DOI： 10.1016/s0140-6736(79)92524-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease - a subjective view.

Authors:  R Horowski
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

Review 2.  Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.

Authors:  H D Langtry; S P Clissold
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

3.  The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats.

Authors:  K Voith
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

4.  Interaction of pergolide with central dopaminergic receptors.

Authors:  M Goldstein; A Lieberman; J Y Lew; T Asano; M R Rosenfeld; M H Makman
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.